Three human and six bovine parainfluenza virus type 3 (PIV3) strains were examined by the use of 60 monoclonal antibodies (MAbs). Fifty-three MAbs to the human C243 strain were directed against six, four, nine and seven epitopes of the haemagglutininneuraminidase (HN), fusion (F), nucleocapsid (N) and matrix proteins, respectively. Seven MAbs to the bovine strain were directed against three epitopes of the HN protein and three epitopes of the F protein. Each strain was characterized in ELISA and immunofluorescence tests with all MAbs and in a haemagglutination inhibition assay with the anti-HN MAbs. There were marked differences between human and bovine viruses, primarily in the HN protein where five epitopes differed. One epitope of the F and one of the N protein also differed. Bovine PIV3 was found to be a homogeneous subtype and distinct from human PIV3.
Parainfluenza virus type 3 (PIV3) belongs to the paramyxovirus genus of the Paramyxoviridae (Kingsbury et al., 1978) . Two different strains have been identified (Abinanti et al., 1961) , one human (Chanock et al., 1958) and one bovine (Reisinger et al., 1959) both causing respiratory tract disease (Wenzel et al., 1972; Frank & Marshall, 1973) . PIV3 consists of at least six structural proteins, the large (L), haemagglutinin-neuraminidase (HN), fusion (F), phospho (P), nucleocapsid (N), and matrix (M) proteins (Galinski et al., 1986; Rydbeck et al., 1986; Sanchez & Banerjee, 1985; Shibuta et al., 1979) . Human and bovine PIV3 share neutralizing epitopes but show distinct antigenic properties (Coelingh et al., 1986; Glezen et al., 1984; Muchmore et al., 1981) . Immunity to PIV3 seems to be limited and reinfections may occur within short time intervals Glezen et at., 1984; Muchmore et al., 1981) . The importance of antibody classes and subclasses in the protection from disease has been discussed (Ray et al., 1988b; Rydbeck et al., 1988b) . No vaccine to prevent the human disease exists, but several attenuated bovine PIV3 vaccines are available for parenteral or intranasal use in animals (Bittle & Muir, 1989) . A field trial of inactivated human PIV3 vaccine has been done but it did not induce resistance to infection (Chin et al., 1969) . Several studies have shown that animals may be protected with whole virus and subunit vaccines containing both human and bovine PIV3 components (Morein et al., 1983; Ray et al., 1985) . The two surface glycoproteins HN and F are important for the establishment of protection against disease (Morein et al., 1983; Spriggs et al., 1987) . A mixture of both 0000-9453 © 1990 SGM surface glycoproteins, HN and F (Ray et al., 1988a) , can induce protection against PIV3, as do HN and F proteins expressed by vaccinia virus and baculovirus recombinants (Spriggs et al., 1987; van Wyke Coelingh et al., 1987) . The aim of this study was to investigate the antigenic stability of bovine PIV3 strains and to compare these strains with selected human strains.
Each strain was characterized in ELISA and immunofluorescence (IF) tests with all monoclonal antibodies (MAbs) ( Table 1 ) and in a haemagglutination inhibition (HI) assay with the anti-HN MAbs ( Table 2 ). The human strains (4051, 10470, C243) were isolated from patients in the U.S.A. and the bovine strains originated in Germany (strain Tiib-E6), Sweden [strains Uppsala (Upp) and U23], U.S.A. [strain Maryland (MD) and the SLP vaccine strain] and Japan (strain 910N). Fifty-three MAbs to the human C243 strain were directed against the HN, F, N and M proteins respectively. Seven MAbs to the bovine strain 910N were also used, four directed to the HN (Boll) protein and three to the F (BoF) protein.
Comparative analysis of the surface glycoproteins showed that the 16 anti-HN MAbs employed in this study identified minimally six epitopes in human PIV3 strains and four epitopes in bovine PIV3 strains (Shibuta et al., 1986) . The reactivities of all anti-human PIV3 HN MAbs with the bovine strains were somewhat restricted and vice versa. Seven anti-HN MAbs reacted with all human and bovine strains (not shown), but MAbs specific for human PIV3 epitopes II1 and IV showed a varying reactivity, indicating that epitope group 111 represented specificities for three different epitopes. No reaction was seen with any bovine strain in tests with The internal proteins showed both a variable and a conserved antigenic profile. Of the 20 MAbs against human PIV3 N protein, 12 reacted with all human and bovine strains. The intratypic variation of the N protein was low. Only MAb 4758 showed a clear difference in one of three recent human isolates, and thus dividing group VI into two different epitopes. Variation among the bovine isolates was somewhat larger. The human PIV3 anti-N MAbs reacted with one or more of all six bovine strains with the exception of 4812 which showed only a weak reaction with the Upp strain in the ELISA. Partial antigenic differences were found with regard to the epitopes detected by MAbs 4613, 4721, 4801, 4804, 4794, 4758 and also the epitope-undefined MAbs 4631 and 4724. These different reactivity patterns show that group III can be further discriminated into three epitopes, and group V into two epitopes. Only minimal variation in the M protein was observed within both human and bovine viruses, i.e. intra-and intersubtypic conservation was high. Eleven of 16 MAbs against human PIV3 M protein reacted with all strains, both human and bovine. Two MAbs (2880 and 4583) showed that one human and one bovine strain lacked one epitope each.
These results demonstrate that the human strains can be distinguished from the bovine strains. They also show that only limited antigenic variation occurs among bovine PIV3 strains recovered at different geographical locations and at various times. With the reagents employed, differences between the human and bovine viral strains were found predominantly in the HN protein among the four proteins studied. Intratypic differences in the HN protein were observed previously (Ray & Compans, 1986; Rydbeck et al., 1988a) . Distinct differences were observed within human PIV3 strains with MAbs 4630 and 4678. The epitopes correlated to the highest neutralization (Rydbeck et al., 1987) , protection (Rydbeck et al., 1988b) and HI, however, were shared by both subtypes as represented by the nine strains examined. This finding corroborates the successful protection experiments of van Wyke Coelingh et al. (1988b) in which bovine PIV3 was used as a vaccine in monkeys challenged with human PIV3. van Wyke Coelingh et al. (1988a) have sequenced the HN genes of six human PIV3 strains and found a high homology among them. The deduced amino acid differences that were found were primarily at the carboxyl and amino termini. The uneven distribution of amino acid diversity was explained by genetic heterogeneity and not a result of mutations accumulated over time. This is most probably the reason for the random antigenic variation observed within both human and bovine subtypes. The intertypic differences between human and bovine strains are more likely to be the result of adaptive mutation over time, possibly due to characteristics of the speciesspecific target cells. The conserved character of human PIV3 F protein was confirmed, and the bovine F protein of the strains in this study was shown to be equally homogeneous. The variability of the internal proteins is not so well known but our study of the differences between human and bovine strains corroborates previous findings of Rydbeck et al. (1987) . There appears to be more variation in the N protein among the bovine strains. The M protein is antigenically conserved. Only homotypic MAbs failed to bind to one strain of each of the human and bovine strains. This means that the variation observed by Rydbeck et al. (1987) between human and Japanese bovine strains does not seem to apply to bovine viruses in general. Genetic conservation of the M protein of several paramyxoviruses has been proposed (Galinski et al., 1986) . The differences between the IF and ELISA results observed in some cases may be caused by processing such as fixation or detergent treatment. This emphasizes the importance of using more than one analytic method. The differences in certain epitopes of the HN protein found in this study may explain the differences between the human and bovine viruses originally observed by Abinanti et aL (1961) and imply that one strain does not induce all possible neutralizing antibodies. However, in addition, intratypic variation in human PIV3 has been shown both genetically and antigenically (van Wyke Coelingh et al., 1985 van Wyke Coelingh & Tierney, 1989) . Conserved epitopes should also be taken into consideration when choosing MAbs for diagnostic purposes. A bovine strain may well induce important neutralizing antibodies (Rydbeck et al., 1987; Shibuta et al., 1986) if used for immunization of humans, but a human strain may induce a wider spectrum of neutralizing antibodies against human PIV3.
